Method for treating demyelinating neuropathy with biotin

Abstract

The invention relates to the use of biotin for treating Amyotrophic Lateral Sclerosis, as well as demyelinating peripheral neuropathies and Neuromyelitis optica (NMO).

1 - 20 . (canceled) 
     
     
         21 . A method for the treatment of a demyelinating neuropathy, comprising administering to a patient in need thereof a composition comprising an amount of biotin sufficient to treat said demyelinating neuropathy. 
     
     
         22 . The method of  claim 21 , wherein the demyelinating neuropathy is a peripheral demyelinating neuropathy. 
     
     
         23 . The method of  claim 21 , wherein the demyelinating neuropathy is a demyelinating neuropathy associated with immunoglobulin M (lgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotein (MAG), typical chronic inflammatory demyelinating polyradiculoneuropathy, atypical chronic inflammatory demyelinating polyradiculoneuropathy, Charcot Marie Tooth la disease and Guillain-Barre syndrome. 
     
     
         24 . The method of  claim 21 , wherein the demyelinating neuropathy is neuromyelitis optica. 
     
     
         25 . The method of  claim 21 , wherein the demyelinating neuropathy is amyotrophic lateral sclerosis. 
     
     
         26 . The method of  claim 21 , wherein a daily amount of biotin administered to the patient is between 50 and 700 mg. 
     
     
         27 . The method of  claim 21 , wherein a daily amount of biotin administered to the patient is at least 100 mg. 
     
     
         28 . The method of  claim 21 , wherein a daily amount of biotin administered to the patient is at least 150 mg. 
     
     
         29 . The method of  claim 21 , wherein a daily amount of biotin administered to the patient is between 100 and 300 mg. 
     
     
         30 . The method of  claim 21 , wherein the composition is in a form suitable for oral administration. 
     
     
         31 . The method of  claim 21 , wherein the composition is in the form of gel capsules, tablets (optionally film-coated), lozenges or pills. 
     
     
         32 . The method of  claim 21 , wherein the composition comprises excipients and biotin as the sole active ingredient. 
     
     
         33 . The method of  claim 21 , wherein the composition is in a form suitable for injectable administration. 
     
     
         34 . The method of  claim 21 , wherein the composition is in a form of a slow release composition. 
     
     
         34 . The method of  claim 21 , wherein the treatment with biotin has a duration of at least 3 months. 
     
     
         35 . The method of  claim 21 , wherein the treatment with biotin has a duration of at least 6 months. 
     
     
         36 . The method of  claim 21 , wherein the treatment with biotin has a duration of at least one year. 
     
     
         37 . The method of  claim 21 , wherein the treatment includes simultaneous, separate or sequential administration of one or more active ingredients in addition to biotin. 
     
     
         38 . The method of  claim 37 , wherein the one or more active ingredients riluzole, baclofen, diazepam trihexyphenidyl, amitriptyline, corticosteroids, plasmapheresis azathioprine, mycophenolate mofetil, rituximab, mitoxantrone, glatiramer acetate, intravenous immunoglobulin (IVIG), and/or cyclophosphamide. 
     
     
         39 . A composition comprising an amount of biotin sufficient to treat a demyelinating neuropathy.